HCAT
Health Catalyst, Inc.
HCAT trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over HCAT overall, supported by stronger fundamentals and lower modeled downside.
HCAT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Healthy | |
| Unavailable |
HCAT's cash flow is currently healthy, but its revenue and profitability are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HCAT PE Valuation
HCAT has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
HCAT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong decline | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect HCAT's earnings and revenue to decline, with profitability weakening. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over HCAT on the outlook, with more favorable earnings and revenue expectations.
HCAT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.84 | -$1.25 |
| Q2 2026 | -$3.69 | -$2.18 |
| Q1 2026 | -$3.73 | -$2.58 |
| Q4 2025 | -$2.55 | -$1.40 |
| Q3 2025 | -$1.59 | -$0.25 |
| Q2 2025 | -$1.51 | -$0.02 |
| Q1 2025 | -$1.15 | +$0.69 |
| Q4 2024 | -$1.15 | +$0.94 |
HCAT lost $2.84 per share over the past year, a bigger loss than the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over HCAT on earnings quality, reporting a profit while its opponent remains loss making.
HCAT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $56.3M | -26% |
| Q2 2026 | $70.5M | -13% |
| Q1 2026 | $70.8M | -11% |
| Q4 2025 | $74.7M | -6.2% |
| Q3 2025 | $76.3M | 0% |
| Q2 2025 | $80.7M | +6.3% |
| Q1 2025 | $79.4M | +6.3% |
| Q4 2024 | $79.6M | +6% |
HCAT's revenue has slid since its 2025 peak: $56M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 89% | +112 points |
| Q2 2026 | -52% | -5.8 points |
| Q1 2026 | -150% | -125 points |
| Q4 2025 | -115% | -93 points |
| Q3 2025 | -23% | -5 points |
| Q2 2025 | -46% | -25 points |
| Q1 2025 | -25% | +5.1 points |
| Q4 2024 | -22% | +22 points |
HCAT has the edge over LLY on profitability, with a higher operating margin.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over HCAT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
HCAT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$2M | -$1.3M |
| Q2 2026 | -$70K | +$8.7M |
| Q1 2026 | $18.2M | +$18.6M |
| Q4 2025 | $9.6M | +$13.6M |
| Q3 2025 | -$719K | -113% |
| Q2 2025 | -$8.8M | -763% |
| Q1 2025 | -$390K | -104% |
| Q4 2024 | -$3.9M | +$15.4M |
HCAT's free cash flow has turned positive again: $26M over the past year, against −$14M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over HCAT on cash flow, with more consistent year-over-year improvement.
HCAT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +2M shares |
| 1 year | +7.9% | +5.6M shares |
| 3 years | +34% | +19.2M shares |
| 5 years | +55% | +26.9M shares |
| Available history | +105% | +38.8M shares |
HCAT has 76M diluted shares, up 7.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $5M |
| Q4 2024 | — |
HCAT hasn't bought back shares in the past year.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over HCAT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
HCAT Net Leverage
HCAT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
HCAT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.4 | Neutral |
| Stochastic | 9.3 | Oversold |
HCAT's weekly RSI is 37 (neutral) and its Stochastic is 9 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
HCAT PE vs Healthcare Sector
HCAT has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
HCAT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.65 | 18% below |
| 20 week MA | $1.79 | 24% below |
| 50 week MA | $1.79 | 24% below |
| 100 week MA | $2.93 | 54% below |
| 200 week MA | $6.18 | 78% below |
HCAT is in a downtrend: it's below all five of its weekly moving averages, and 78% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over HCAT on trend strength, trading above more of its moving averages.
HCAT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $34.1 | $44.9 | +31% |
| 2021 | $44.9 | $39.5 | -12% |
| 2022 | $39.5 | $10.3 | -74% |
| 2023 | $10.3 | $9.26 | -10% |
| 2024 | $9.26 | $7.08 | -24% |
| 2025 | $7.08 | $2.42 | -66% |
| 2026 YTD | $2.42 | $1.36 | -44% |
HCAT has finished five years in a row lower, and it's down 44% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over HCAT on returns for 2026, with the stronger performance.